Nanomedicine approaches for prevention of inflammation-induced preterm birth

预防炎症引起的早产的纳米医学方法

• 批准号: 10591822
• 负责人: IRINA BURD
• 金额: $ 7.22万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-13 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10591822
• 关键词: 37 weeks gestation; Address; Birth; Birth Rate; Brain; Brain Injuries; Caproates; Cells; Cerebral Palsy; Cervix Uteri; Clinical Trials; Cognitive; Complex; Cream; Data; Development; Dose; Drug Combinations; Drug Delivery Systems; Drug Kinetics; Drug Targeting; Drug Transport; Excipients; Exposure to; Female; Formulation; Gene Expression; Gene Expression Profiling; Histone Deacetylase Inhibitor; Human; Hydroxyprogesterone; Immune; Immune response; Immune system; Immunologics; Impaired cognition; In Vitro; Infant Care; Inflammation; Inflammatory Response Pathway; Injections; Label; Lead; Live Birth; Measures; Membrane; Methods; Modeling; Mucous Membrane; Mus; Myometrial; Neonatal; Neuroimmune; Outcome; Penetration; Perinatal Brain Injury; Pharmaceutical Preparations; Pharmacotherapy; Placenta; Pregnancy; Premature Birth; Premature Labor; Prevention; Prevention approach; Progesterone; Receptor Gene; Recording of previous events; Route; Schizophrenia; Supplementation; Synthetic Progestogens; Therapeutic; Therapeutic Effect; Tissues; Tocolytic Agents; Toxic effect; Trichostatin A; Uterine Contraction; Uterus; Vagina; Vaginal delivery procedure; Validation; Withdrawal; Woman; autism spectrum disorder; base; delayed birth; design; drug candidate; drug market; effective therapy; fetal; fetal inflammatory response syndrome; healthy pregnancy; immunoregulation; improved; in vivo; indexing; infant death; innovation; intrauterine inflammation; maternal risk; mouse model; myometrium; nanoformulation; nanomedicine; neurobehavioral; novel; preclinical study; premature; prenatal exposure; prevent; pup; receptor expression; reproductive; reproductive tract; side effect; targeted treatment; treatment effect; zeta potential

Preterm birth (PTB), or birth before 37 weeks of gestation, was the second leading cause of infant death in the US in 2017. Each year, more than $26 billion is spent on treatment and care of babies born prematurely, not accounting for the lifelong impact of developmental and cognitive impairments. Here, we focus on the most common cause of PTB, inflammation. Maternal inflammation triggers a pro-inflammatory cytokine response that can also lead to fetal inflammatory response syndrome and perinatal brain injury. Brain injury leads to a spectrum of adverse neurobehavioral outcomes, including cerebral palsy, autism, schizophrenia, and cognitive delay among others. The only approved drug for prevention of PTB is the synthetic progestin hydroxyprogesterone caproate (OHPC) dosed systemically as weekly injections in women with a singleton pregnancy with a history of singleton spontaneous PTB, and a recently failed confirmatory study has led to calls for the FDA to withdraw the drug from the market. For women that are already in preterm labor, off-label tocolytics (anti-contraction medications) may be given to slow uterine contractions, but this typically only delays birth for a few days. New, effective treatments for preventing PTB are desperately needed. Further, the vaginal route of administration is underexplored but highly promising; vaginally absorbed drug is preferentially transported to the uterus. We have demonstrated that by increasing mucosal drug penetration and eliminating hypertonic excipients that cause local toxicity, increased drug delivery to target reproductive tissues can be achieved. In the setting of intrauterine inflammation, we have observed that combining vaginal progesterone (P4) with drugs that favor non-laboring states of P4 receptor and gene expression, such as histone deacetylase inhibitors (HDACi), provides a significant increase in dams that go on to deliver live pups. In contrast, dosing the same drug combination systemically or injecting the approved product OHPC had no therapeutic effect. Analysis of gene expression changes suggest that quiescing myometrial activity was key, and we have confirmed that the myometrial tissue levels of P4 and HDACi measured after vaginal combination delivery in mice were also the most effective in preventing human myometrial cell contractility. Importantly, preliminary neurobehavioral analysis of pups born after exposure to intrauterine inflammation followed by vaginal P4/HDACi suggests that development occurred similar to pups that had not been exposed to intrauterine inflammation. Herein, we propose studies that build from exciting preliminary data using nanomedicine to address fundamental questions regarding route of administration, pharmacokinetics, as well as validating existing drug classes that may be reformulated and repurposed for improved targeting to the female reproductive tract. If these preclinical studies progress as expected, we will have identified novel, effective methods for prevention of inflammation-induced PTB that also support fetal and neonatal immunological programming and development.

早产（PTB），即妊娠37周之前出生，是2017年美国婴儿死亡的第二大原因。每年，超过260亿美元用于治疗和护理早产儿，这还不包括发育和认知障碍的终身影响。在这里，我们关注PTB最常见的原因，炎症。母体炎症引发促炎细胞因子反应，也可导致胎儿炎症反应综合征和围产期脑损伤。脑损伤导致一系列不良神经行为结果，包括脑瘫、自闭症、精神分裂症和认知延迟等。唯一批准用于预防PTB的药物是合成的孕酮己酸羟孕酮（OHPC），每周全身注射一次，用于有单胎自发性PTB病史的单胎妊娠妇女，最近失败的验证性研究导致FDA要求将该药物从市场上撤回。对于已经早产的妇女，可以使用标签外的宫缩抑制剂（抗收缩药物）来减缓子宫收缩，但这通常只会延迟分娩几天。迫切需要预防PTB的新的有效治疗方法。此外，阴道给药途径尚未充分探索，但非常有前途;阴道吸收的药物优先转运至子宫。我们已经证明，通过增加粘膜药物渗透和消除引起局部毒性的高渗赋形剂，可以实现向靶生殖组织的药物递送增加。在子宫内炎症的情况下，我们已经观察到，将阴道孕酮（P4）与有利于P4受体和基因表达的非劳动状态的药物（如组蛋白脱乙酰酶抑制剂（HDACi））相结合，可以显著增加继续分娩活仔的母鼠数量。相反，全身给予相同的药物组合或注射批准的产品OHPC没有治疗作用。基因表达变化的分析表明，静止子宫肌层活性是关键，我们已经证实，阴道联合分娩后测量的小鼠子宫肌层组织中P4和HDACi水平也是预防人类子宫肌层细胞收缩性最有效的。重要的是，对暴露于子宫内炎症后出生的幼鼠进行的初步神经行为分析表明，发育与未暴露于子宫内炎症的幼鼠相似。在此，我们提出了利用纳米医学从令人兴奋的初步数据中建立的研究，以解决有关给药途径，药代动力学以及验证现有药物类别的基本问题，这些药物类别可以重新配制和重新用于改善女性生殖道的靶向。如果这些临床前研究进展如预期，我们将确定新的，有效的方法来预防炎症诱导的PTB，也支持胎儿和新生儿的免疫编程和发展。